Biomarkers in Gastrointestinal Cancer: Focus on Colon, Pancreatic and Gastric Cancer by Vanessa Deschoolmeester et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
Biomarkers in Gastrointestinal Cancer:  
Focus on Colon, Pancreatic and Gastric Cancer 
Vanessa Deschoolmeester*, Filip Lardon,  
Patrick Pauwels and Marc Peeters 
Center for Oncological Research (CORE) Antwerp,  
Laboratory of Cancer Research and Clinical Oncology,  
University of Antwerp,  
Belgium 
1. Introduction 
Personalized cancer medicine based on genetic profiling of individual tumors is regarded as 
the treatment strategy of the future. The targeted drugs for the treatment of cancer have 
rapidly developed. However, our understanding (at the molecular level) of the precise role 
that potential targets have in tumorigenesis, and the survival dependence of tumors on 
these components, has not progressed at the same rate (De Roock et al., 2011). Since patient 
selection for therapy remains problematic, there has been an increasing interest in 
biomarkers of cancer risk in predicting future patterns of disease. In the broadest sense, a 
biomarker is any biological, chemical, or biophysical indicator of an underlying biological 
process. From a medical perspective, a biomarker is a physiological characteristic that is 
indicative of health and disease. A cancer biomarker has been defined as “a molecular, 
cellular, tissue, or process-based alteration that provides indication of current, or more 
importantly, future behavior of cancer” (Hayes et al., 1996). Cancer biomarkers are 
employed across the entire healthcare spectrum from the cancer biological research 
laboratory to patient monitoring in the clinic. Clinical applications include disease risk 
stratification, chemoprevention, disease screening, diagnosis and prognosis/prediction, 
treatment planning and monitoring, and posttreatment surveillance. Cancer biomarkers 
have contributed greatly to our current understanding of the heterogeneous nature of 
specific cancers and have led to improvements in treatment outcomes. However,  
full adoption of cancer biomarkers in the clinic has been slow to date, and only a limited 
number of cancer biomarker products are currently in routine use 
(http://www.insightpharmareports.com/reports_report.aspx?r=559&id=78452). Two 
primary challenges in developing cancer biomarkers are the discovery of candidate markers 
and the validation of those candidates for specific uses. The discovery process depends on 
the technologies available, and their sensitivity and specificity, to investigate the complex 
biochemistry of health and disease in order to identify differences that can be detected 
consistently in diverse populations. The validation process is also arduous and costly, often 
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requiring collection of or access to many patient samples with extensive clinical annotation 
and long-term follow-up. In addition, a biomarker must be validated for each specific 
application for which it will be used. There must be convincing evidence that a surrogate 
endpoint accurately predicts the clinical endpoint of interest or in the case of screening, a 
test must have sufficient sensitivity, specificity, and positive predictive value to accurately 
identify a disease in the general population (US National Academy Press, Institute of 
Medicine (U.S.). Committee on Developing Biomarker-Based Tools for Cancer Screening, 
Diagnosis, and Treatment, 2007). Rapidly growing insights in the molecular biology of 
cancer and recent developments in gene sequencing, global gene expression profiling or 
genome wide analysis have led to high expectations for the identification, validation and 
assessment of cancer biomarkers alongside the established “standards of care” for cancer 
diagnosis and treatment.  
In this review, the most promising biomarkers in gastrointestinal cancer are discussed, 
focusing on the epidermal growth factor receptor (EGFR)-pathway in colon cancer, the 
serum biomarkers, the glucose transporter (GLUT) receptors, and human equilibrative 
nucleoside transporter 1 in pancreatic cancer and HER2 in gastric tumors.  
2. Colon cancer 
2.1 Introduction 
Colorectal cancer (CRC) is a major public health problem. CRC results from the cumulative 
effects of sequential genetic alterations, leading to a progressive and irreversible loss of 
normal control of cell growth and differentiation. Treatment of CRC consists of complete 
surgical removal of the primary tumor and the regional lymph nodes. Despite 
improvements in surgical techniques, dosing and scheduling of adjuvant and neo-adjuvant 
systemic therapy, five year survival for early stage colorectal cancer, i.e. without invasion or 
lymph node metastases, is about 90%, but this falls of to 65% for tumors with regional 
spread and to 10% for late stage disease in which the cancer has metastasized to distant sites 
(Deschoolmeester et al., 2010). Currently, the tumor-node-metastasis (TNM) stage is the only 
proven prognostic marker to aid in the identification of patients with aggressive disease 
(Tejpar et al., 2010). However, its predictive value is limited because even the outcome 
within each stage group is not homogeneous (Deschoolmeester et al., 2010). CRC should be 
regarded as a heterogeneous disease defined by different activating mutations in receptor 
tyrosine kinases (RTKs), or activating or loss of function mutations in downstream 
components of the RTK-activated intracellular pathways, some of which could occur in the 
same tumor. The efficacy of targeted drugs is therefore linked to the specific molecular 
alterations in the tumor (De Roock et al., 2011). The availability and application of various 
treatment modalities in CRC has resulted in the elucidation of prognostic and predictive 
biomarkers that will improve outcome through patient classification and selection for 
specific therapies. A prognostic biomarker provides information about the patient’s overall 
outcome, regardless of therapy, whereas a predictive marker gives information about the 
effect of a particular therapeutic intervention (Tejpar et al., 2010). Consequently, in recent 
years a huge amount of research has been devoted to the study of new biological 
prognostic/predictive markers as recently reviewed by our group (Deschoolmeester et al., 
2010). Several criteria must be met to ensure a biomarker is clinically useful. In addition, the 
biomarker needs to be tested and validated in a large cohort of randomized patients. 
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Although hundreds of these markers have been proposed in the last 2 to 3 decades, the 
current reality is that no molecular marker, other than the KRAS gene in the case of 
epidermal growth factor receptor (EGFR)-targeted therapy for metastatic disease, has made 
it into clinical practice (Duffy & Crown, 2008)(De Roock et al., 2009).  
EGFR is a receptor tyrosine kinase belonging to the HER-family. When activated, EGFR 
phosphorylates and activates other intracellular proteins that affect cell signaling pathways, 
(Harding & Burtness, 2005) cellular proliferation, and control of apoptosis and angiogenesis 
(Figure 1) (Tedesco et al., 2004)(Harding & Burtness, 2005). EGFR has been implicated in 
colorectal tumorigenesis, tumor progression, and metastasis, as reviewed in Lockhart and 
Berlin (Lockhart et al., 2005)(Ng & Zhu, 2008). Overexpression of EGFR has been described 
in up to 65%–70% of human colon tumors and has been associated with the progression of 
CRC to a more advanced stage (Ng & Zhu, 2008). Therefore, EGFR not only represents a 
possible prognostic marker in the adjuvant setting of primary tumors but primarily a 
rational molecular target for a new class of anticancer agents, especially in the setting of 
metastatic CRC (mCRC) (Scartozzi et al., 2006a)(Scartozzi et al., 2006b)(Overman & Hoff, 
2007).  
 
Fig. 1. EGFR signaling pathways and its main transduction pathways.  
In preclinical studies, it was found that the inhibition of EGFRs had antitumor activity, and 
available data suggests synergy with both chemotherapy and radiotherapy (Rivera et al., 
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2008). EGFR signaling can be targeted by either monoclonal antibodies (moAb) (cetuximab 
and panitumumab) or tyrosine kinase inhibitors (TKIs). Cetuximab (a mouse chimeric IgG1) 
and panitumumab (a fully human IgG2) block ligand induced EGFR tyrosine kinase 
activation, thereby probably preventing downstream activation of phosphatidylinositol 3-
kinase (PI3K)/AKT and RAS/MAPK (mitogen activated protein) signaling pathways, 
resulting in inhibition of cellular proliferation and induction of apoptosis (Deschoolmeester 
et al., 2010). Nowadays, anti-EGFR targeted therapy is undergoing extensive clinical 
evaluation as single agents and in combination with chemotherapy for the treatment of 
recurrent or first-line mCRC (as reviewed by (Deschoolmeester et al., 2010)). Results of these 
studies have demonstrated a manageable and acceptable toxicity profile and a promising 
level of activity. Initially, these therapies were given to unselected populations, but novel 
insights based on the independent reanalysis of eight randomized trials suggested that these 
therapies would be effective only in wild type KRAS populations (Allegra et al., 2009). Based 
on these results, the recommended use of these drugs was amended by both the European 
Medicine Agency (EMEA) and the U.S. Food and Drug Administration (FDA), with 
important differences, however. The FDA issued a recommendation in 2009 against the use 
of these drugs in patients with tumors mutated in codon 12 or 13 of KRAS, but a label 
change of the drugs will require additional validation of a single mutation detection assay 
and reassessment of all randomized trials using this assay. In Europe, the EMEA changed 
the approval of these drugs for use in wild-type KRAS populations only. This has important 
implications because the exact mutations to be tested are not specified nor is the 
methodology (see further below) (Bellon et al., 2011).  
2.2 KRAS 
KRAS belongs to the RAS family of genes (KRAS, NRAS and HRAS) that encode guanosine-
5’-triphosphate (GTP)-binding proteins. KRAS is an important effector of ligand-bound 
EGFR, mainly, but not exclusively through BRAF and MAPK axis. KRAS can also activate 
PI3K through direct interaction with its catalytic subunit (Figure 1) (De Roock et al., 2011). 
Mutations in the KRAS gene are found in 30-40% of CRC and these mutations disable the 
GTPase activity, causing tumor-associated KRAS to accumulate in the active GTP-bound 
conformation. About 85-90% of these mutations occur in codons 12 and 13 while the 
remaining mutations occur in codon 61 (5%) and 146 (5%). The most frequent types of 
mutations detected are glycine to aspartate on codon 12 (p.G12D, 36.0%), glycine to valine 
on codon 12 (pG12V, 21.8%), and glycine to aspartate on codon 13 (p.G13D, 18.8%) 
(Neumann et al., 2009). Several retrospective studies (single-group and randomized clinical 
trials, summarized by Allegra and colleagues (Allegra et al., 2009)) confirmed the finding by 
Lievre and colleagues (Lièvre et al., 2006) that mutant KRAS is a predictor of resistance to 
EGFR moAb. This discovery led to the first practical implication of personalized medicine in 
mCRC. All patients with mCRC are now profiled for seven mutations in KRAS codons 12 
and 13 before receiving cetuximab or panitumumab (De Roock et al., 2011). However, the 
picture is not that simple. There is growing evidence for the existence of a whole orchestra 
of variables and mutations that influence the responsiveness to an anti-EFGR treatment and 
their role is not fully understood. A European consortium study showed that codon 61 
mutations had an adverse effect similar to codon 12 mutations, whereas codon 146 
mutations did not affect cetuximab efficacy. Codon 146 mutations co-occurred with other 
KRAS mutations, an additional indication that this might not be an important oncogenic 
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codon (De Roock et al., 2010b). In vitro data also suggest that KRAS codon 13 mutations 
have a weaker transforming activity than codon 12 mutations and some reports also suggest 
that some of these patients do respond to cetuximab (Koch et al., 2011). Based on these 
findings, de Roock and colleagues performed a thorough retrospective subgroup analysis in 
a pooled data set of 579 patients with chemotherapy-refractory CRC. Their data puzzles the 
picture of the negative predictive value of a KRAS mutation, because patients with the 
p.G13D mutation seem to respond to cetuximab therapy, in contrast to other KRAS mutated 
tumors, albeit with a lower response rate than those with KRAS wild type tumors. The 
prolonged progression-free and overall survival of patients with p.G13D-mutated tumors in 
comparison with those with other KRAS- mutated tumors may not be due to a real 
reduction in tumor burden but to a delay in progression. A possible explanation of this 
clinical observation is that p.G13D mutant tumors do not undergo apoptosis (cytotoxic 
effect) on EGFR inhibition, but proliferation is inhibited (cytostatic effect). However, 
prospective randomized trials are needed before conclusions about potential beneficial 
effects of cetuximab in p.G13D-mutated chemotherapy refractory metastatic colorectal 
cancer should be inferred (De Roock et al., 2010a). 
Furthermore, mutations in the KRAS gene can be detected by several different molecular 
methods and no gold standard methodology is currently available. Because the correctness 
of the KRAS test results is of utmost importance for good patient care, a quality control 
scheme was set up to (a) assess the performance of KRAS testing in Europe, (b) provide 
remedial measures if necessary, and (c) ensure uniform performance over time by repeated 
testing rounds. In total, 59 laboratories from eight different European countries participated 
in the regional KRAS external quality assessment (EQA) scheme in 2009. Only 70% of 
laboratories correctly identified the KRAS mutational status in all 10 samples. Genotyping 
mistakes can be the result of several reasons. A very important issue is the starting material 
and the type of fixative used. Another important issue in KRAS genotyping is the method 
used for testing. The TheraScreen®DxS kit is considered to be the gold standard for KRAS 
testing in Europe for diagnostic use. However, in this EQA scheme, several mistakes were 
made using this kit. In addition, the kit is designed to detect only one mutation in a sample, 
and therefore the mutation scoring ignores possible double mutations, interpreting it as 
crosstalk. Furthermore, there was a very high variability among laboratories in the 
estimation of the percentage of tumor cells in H&E stained paraffin sections and the general 
quality of the reports received in the context of this EQA scheme were very poor. 
Incomplete or inaccurate exams lead to incorrect diagnoses and can have important 
consequences for a patient. Therefore, further development of the KRAS EQA scheme aims 
to provide a baseline picture of the accuracy and reliability of the analysis of the KRAS test, 
to identify areas of particular difficulty in testing procedures and to provide a mechanism 
for improvement for the participating laboratories (Bellon et al., 2011).  
In addition, up to 50-65% of patients with KRAS wild-type tumors are resistant to EGFR 
moAb therapies. Therefore the quest for predictive markers continues. Genetic alterations in 
other EGFR effectors, acting downstream of KRAS together with alternative KRAS 
mutations (in codon 61 and 146) could drive primary resistance to anti-EGFR therapy and 
are currently investigated (Sartore-Bianchi et al., 2009a)(Molinari et al., 2009)(Souglakos et 
al., 2009)(Laurent-Puig et al., 2009)(Meriggi et al., 2009)(Prenen et al., 2009)(Loupakis et al., 
2009a)(Loupakis et al., 2009b)(Perrone et al., 2009)(De Roock et al., 2011). Moreover, Sartore-
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Bianchi et al., described that when expression of PTEN and mutation of KRAS, BRAF and 
PIK3CA are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to 
anti-EGFR therapies can be identified (Sartore-Bianchi et al., 2009a).  
It is unclear to what extent the effects of mutant KRAS are the same for other RTK-targeted 
therapies. It is possible that KRAS-mutant tumors are not dependent on any RTK upstream 
component, and therefore will not respond to drugs targeting these RTKs. Alternatively, it 
might be that KRAS mutations confer only part of the survival advantage needed for tumor 
cells, and therefore will still benefit from RTK inhibition. Moreover, to define CRC as KRAS 
mutant versus KRAS wild-type probably underestimates additional heterogeneity found 
within both populations (De Roock et al., 2011).  
2.3 BRAF 
BRAF, a member of the RAF gene family (ARAF, BRAF and CRAF), encodes a serine-
threonine protein kinase, downstream of activated KRAS, and initiates a mitogenic kinase 
cascade leading to cell proliferation (Figure 1). Activating mutations of BRAF have been 
reported in 5–15% of CRC and >95% of all known mutations involve a thymine to adenine 
transversion in nucleotide 1799, which leads to a substitution of valine by glutamic acid at 
amino acid residue 600 (V600E), which results in an upregulation of the ERK signaling 
pathway independently of KRAS mutation (Nash et al., 2010)(Barault et al., 2008)(Oliveira et 
al., 2004). In addition, the V600E mutation could have additional functions, since KRAS and 
BRAF mutations seems to be mutually exclusive in CRC, with very rare exceptions, 
suggesting they occur in different tumor types and have different outcomes. Moreover, 
BRAF mutations are associated with sporadic microsatellite instability (MSI), CpG island 
methylator phenotype (CIMP) and right sided tumors, whereas mutant KRAS are not (De 
Roock et al., 2011)(Dasari & Messersmith, 2010).  
BRAF mutation status appears to be a valid negative prognostic marker for CRC in the 
adjuvant and metastatic setting, as demonstrate in the PETACC-3 (Roth et al., 2010), the 
CRYSTAL (Van Cutsem et al., 2011) and other studies (Yokota et al., 2011)(Park et al., 2011). 
The presence of CIMP-high appears to eliminate, at least in part, the adverse effect of BRAF 
mutations, whereas the good prognosis associated with MSI-high was abrogated in the 
presence of a BRAF mutation (Ogino et al., 2009a). In contrast, Samowitz et al. (Samowitz et 
al., 2005) and Roth et al. (Roth et al., 2010) found that BRAF mutations were associated with 
a significantly poorer survival in MSS tumors, but had no effect on the excellent prognosis 
of MSI-high tumors. Therefore, it has been postulated that it is not the BRAF mutation itself 
which confers a poor prognosis but rather that the mutation has different effects depending 
on the type of genetic pathway in which it is produced (Barault et al., 2008).  
In addition, the currently available data suggest that the BRAF V600E mutation confers 
resistance to EGFR moAb in patients with chemotherapy-refractory KRAS wild-type mCRC 
and might be used as an additional predictive factor in this setting (Siena et al., 
2009)(Laurent-Puig et al., 2009)(Sartore-Bianchi et al., 2009a)(Di Nicolantonio et al., 2008)(Tol 
et al., 2009).  
Furthermore, the treatment of KRAS-mutated CRC with a selective BRAF inhibitor could be 
an interesting approach since BRAF is an important effector downstream of KRAS in the 
ERK signaling pathway. Phase II clinical trials are currently ongoing with the combination 
of sorafinib (BRAF inhibitor) with either FOLFOX, FOLFIRI or cetuximab.  
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2.4 PIK3CA 
The PI3Ks are a family of lipid kinases grouped into three classes with different structure 
and substrate preferences. Class 1 phosphatidylinositol 3-kinases (PIK3) are heterodimeric 
proteins composed of a p85 regulatory subunit and one of several p110 catalytic subunits. 
Among several isoforms of the catalytic subunits, only the α-type, PIK3CA, has been shown 
to harbor oncogenic mutations or amplifications in its gene in human malignancies (Ogino 
et al., 2009b)(Jang et al., 2010). Activation of class I PI3K is initiated when a growth factor 
binds to its cognate RTK, which includes members of the ERBB-family, platelet-derived 
growth-factor receptor (PDGFR) and the insulin and the insulin-like growth-factor 1 
receptors (IGF1R) (De Roock et al., 2011). Activated PIK3CA will phosphorylate 
phosphatidyl-inositol-4,5-biphospate (PIP2) to produce phosphatidyl-inositol-3,4,5-
triphospate (PIP3) which localizes the serine threonine kinase Akt to the cell membrane 
where it becomes activated (Figure 1). Activated Akt phosphorylates downstream protein 
effectors and amplifies the signaling cascade, enhancing cell proliferation and survival 
(Ogino et al., 2009b). Based on the current data, it seems that PIK3CA mutation frequency in 
CRC is probably between 15 and 25% (Dasari & Messersmith, 2010). More than 80% of 
PIK3CA mutations in CRC occur in exon 9 (60-65%) or exon 20 (20-25%). Mutation in 
PIK3CA can co-occur with KRAS and BRAF mutations. A European consortium recently 
suggested that only PIK3CA exon-20 mutations are associated with a lack of cetuximab 
activity in KRAS wild-type tumors (De Roock et al., 2010b). However, because of the low 
frequency of this mutation, these data require confirmation in large patient population 
studies. In contrast, PIK3CA exon-9 mutations are associated with KRAS mutations and do 
not have an independent effect on cetuximab efficacy (De Roock et al., 2010b). The apparent 
difference between exon-9 and exon-20 mutations could explain the conflicting data 
regarding PIK3CA mutations reported by Sartore-Bianchi and colleagues (Sartore-Bianchi et 
al., 2009b) (lack of response to cetuximab and more exon-20 mutations) and Prenen and 
colleagues (Prenen et al., 2009) (no correlation). PIK3CA mutations as a whole were 
associated with shorter cancer specific survival in a series of surgically resectable CRC, but 
exon-9 and exon-20 were not studied separately (Ogino et al., 2009b)(Kato et al., 2007). More 
studies on large patient populations are needed to establish the prognostic role of PIK3CA 
exon-9 and exon-20 mutations.  
2.5 PTEN 
PI3K-initiated signaling is inhibited by phosphatase tensin homologue (PTEN). The PTEN 
protein acts as a phospholipid phosphatase with PIP3 as a substrate. PIP3 is an important 
lipid second messenger that provides docking sites for multiple downstream components, 
including AKT, which is activated by phosphorylation and inhibited by PTEN (Figure 1). 
Since PTEN protein is a negative regulator of the AKT signaling pathway, inactivation of 
PTEN, which is a common event in human malignancies, facilitates cell proliferation and 
apoptosis (Sawai et al., 2008)(Goel et al., 2004). PTEN activity may be lost trough various 
mechanisms, including mutations, deletions, silencing, allelic losses at chromosome 10q23 or 
hypermethylation of the PTEN promoter region (especially in MSI-high CRC). Therefore, 
ascertainment of PTEN status is usually done on protein level and the recorded frequency of 
loss of PTEN expression varies from 19% to 36% in CRC. Data on the loss of PTEN are not 
concordant between primary and metastatic tumors (De Roock et al., 2011)(Dasari & 
Messersmith, 2010). In addition, PTEN loss in metastatic tumors predicted lack of response 
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to cetuximab and PTEN null metastasis had shorter progression free survival, which was 
even more significant in KRAS wild-type patients. In sharp contrast, the PTEN analysis on 
the primary tumor did not reveal any predictive or prognostic information. Although the 
relative low concordance rate between the primary and metastatic tumors for PTEN 
expression could be secondary to selection of clonal populations during metastasis, it could 
be the subjective nature of immunohistochemistry testing with significant method and 
observer variability. This consideration and the possible need to analyze PTEN from 
metastatic tumors may limit the role of PTEN as biomarker in CRC (Dasari & Messersmith, 
2010).  
2.6 Conclusion 
In summary, both MAPK and PI3K pathways are stimulated by EGFR, with important 
implication for EGFR targeted therapy and future drug development. Current American 
Society of Clinical Oncology (ASCO) guidelines recommend testing only for KRAS 
mutations in codon 12 and codon 13, in patients being considered for EGFR moAb therapy 
(Dasari & Messersmith, 2010). However, evidence shows that other molecular alterations, 
such as BRAF, PIK3CA (exon-20) mutations or loss of PTEN expression, could preclude 
response to EGFR moAb. The subjective nature of PTEN assessment, however, is a 
significant challenge. In addition, new drugs are being developed against numerous targets 
in these pathways, and many are in early clinical stages. Finally, a better understanding of 
the functional interactions within RTK-activated intracellular pathways is essential to target 
the individual tumor and to deliver more effective medical treatment to patients with 
mCRC. Furthermore, the ability of the cancer cell to develop drug resistance via new 
mutations or alternative signaling pathways also needs to be addressed by combination 
therapy, and, if possible, analysis of tumor tissue upon progression (Dasari & Messersmith, 
2010)(De Roock et al., 2011).  
3. Pancreatic cancer 
3.1 Introduction 
Pancreatic cancer has the worst prognosis of all gastrointestinal malignancies with the 
mortality approaching the incidence (Buxbaum & Eloubeidi, 2010)(Bünger et al., 2011). Late 
clinical presentation, intrinsic biological aggressiveness, and resistance to conventional 
chemotherapy and radiotherapy represent the predominant reasons for its poor prognosis 
(Pizzi et al., 2009). This demonstrates an urgent demand for improved screening tools for 
early detection (Buxbaum & Eloubeidi, 2010)(Bünger et al., 2011). While surveillance is 
performed in individuals with genetic syndromes, hereditary pancreatitis, and a strong 
family history there are no clear guidelines for those with clinical risk factors like diabetes 
mellitus, tobacco use, and chronic pancreatitis (Buxbaum & Eloubeidi, 2010). Pancreatic 
ductal adenocarcinoma is the most commonly diagnosed pancreatic neoplasm, and reported 
to be the forth or fifth leading cause of cancer death in Western countries. Diagnosis of 
pancreatic cancer at early stages is crucial because successful surgical resection remains the 
only possibility of cure (Ansari et al., 2011). Only 10-30% of pancreatic tumor patients are 
operated on with curative intent. The expected 5-year survival rate of R0 resected patients 
with additional adjuvant chemotherapy is about 4-26%. In contrast, for the remaining 
patients who present with unresectable UICC stage III and IV carcinomas, no curative 
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therapy is available. These patients have median survival times of 8-12 months (stage III) 
and 5-8 months (stage IV), respectively (Bünger et al., 2011). In addition, early-stage 
pancreatic cancer is usually clinically silent, and symptoms only become apparent after the 
tumor invades surrounding tissues or metastasis to distant organs. Therefore, most persons 
who present with symptoms attributable to pancreatic cancer have advanced disease 
(Vincent et al., 2011).  
The Holy Grail for pancreatic cancer investigators is to identify early markers, which predict 
the development of pancreatic cancer, uncover early resectable disease, and guide therapy 
(Buxbaum & Eloubeidi, 2010).  
Potential molecular markers are sought in the pancreatic tissue, juice as well as other body 
fluids including serum and urine. An important consideration is that pancreatic tumor cells 
and secreted molecules are found in markedly higher concentrations in the pancreas and 
pancreatic juice compared to serum. Additionally, molecules and proteins in the serum are 
overwhelmed by high concentrations of albumin, transferrin, and immunoglobulins 
(Buxbaum & Eloubeidi, 2010).  
Both hypothesis driven and high throughput searches for molecular markers to predict 
disease, early diagnosis, and treatment response are underway. Challenges include 
differentiation of cancer from chronic inflammatory disease of the pancreas and achieving 
reproducible results among diverse patients. Minimally invasive methods including 
endoscopic ultrasound guided fine needle aspiration (EUS-FNA) to acquire tissue may 
facilitate these important efforts (Buxbaum & Eloubeidi, 2010). This method enabled not 
only accurate diagnosis, but also the collection of cancer tissue before surgery or 
chemotherapy even in inoperable cases. Evaluation of the expression status of multiple 
molecules within the FNA specimen will lead to the establishment of individualized 
therapeutic strategies based on the prediction of prognosis or response to chemotherapy 
(Hamada & Shimosegawa, 2011).  
3.2 Serum biomarkers 
Improved screening for early diagnosis is essential in order to increase the rate of curatively 
resectable carcinomas, thereby ameliorating patient’s prognosis. In present clinical practice, 
screening for pancreatic cancer is based on state-of-the-art imaging or even invasive 
diagnostics. A relatively non-invasive, cost efficient possibility could be provided by the 
measurement of disease-specific markers in peripheral blood. A wide range of serum 
markers has been reported to be elevated in pancreatic cancer patients since the eighties. 
Despite these many markers or their combinations with high diagnostic potential for 
pancreatic cancer screening, none of them have achieved the levels of sensitivity and 
specificity necessary to be recommended as a screening tool for asymptomatic patients in 
the general population (Bünger et al., 2011)(Xu et al., 2011). Only a few markers have shown 
promising results in recent studies with CA19-9 being the most widely investigated and 
evaluated single marker (Bünger et al., 2011).  
3.2.1 CA19-9 
The best-established marker is CA19-9, which is a sialylated Lewis antigen of the MUC1 
protein with an overall sensitivity ranging from 41 to 86% and specificity from 33 to 100% 
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(Bünger et al., 2011)(Buxbaum & Eloubeidi, 2010). As a marker for early pancreatic cancer, 
there are some important weaknesses. Approximately 10% of the population with the 
Lewis-negative genotype is not able to produce CA19-9, secondary to a lack of the enzyme 
involved in its synthesis, even if they have advanced pancreatic cancer. Recently it has been 
reported that patients with undetectable CA19-9 have a better prognosis than those with 
elevated levels. Patients with small pancreatic cancers often show false negative CA19-9 
values, thus eliminating its value in early diagnosis. In addition, patients with certain blood 
types are incapable of expressing the antigen recognized by CA19-9. Moreover, CA19-9 
elevation is common in patients with obstructive jaundice even without malignancy because 
of the reduction in clearance by the cholestatic liver. Furthermore, false positive CA19-9 
elevation is also frequently observed in patients with cancers of the upper gastrointestinal 
tract, ovarian cancer, hepatocellular cancer, benign conditions of the hepatobiliary system 
and chronic pancreatitis (Xu et al., 2011). Nevertheless, continuous evaluation of this marker 
strongly suggests progressive disease during chemotherapy or recurrence after operation 
(Hamada & Shimosegawa, 2011). Thus CA19-9 is considered the standard for monitoring 
response to chemotherapy and recurrence following surgical resection in patients with 
pancreatic cancer but not for the initial diagnosis of the disease in the asymptomatic 
population (Xu et al., 2011)(Buxbaum & Eloubeidi, 2010)(Vincent et al., 2011).  
In addition to serum it has been shown that pancreatic juice might also be a source of 
pancreatic cancer tumor markers. Several groups evaluated the diagnostic value of CA19-9 
in pancreatic juice. Some groups found that CA19-9 concentrations were significantly higher 
in patients with cancer than in patients with chronic pancreatitis and other non-neoplastic 
patients (Malesci et al., 1987) showing a diagnostic value approximately similar to that of 
serum CA19-9 (Nishida et al., 1988)(Chen et al., 1989). Other studies could not confirm the 
diagnostic value of CA19-9 in pancreatic juice (Matsumoto et al., 1994). Further investigation 
into the exact role of CA19-9 in pancreatic juice is required. However, other potentially 
interesting biomarkers, like KRAS mutations, 90K, CEA were identified in this pancreatic 
juice and need further investigation (Nakaizumi et al., 1999)(Gentiloni et al., 1995).  
3.2.2 Micro-RNA 
Small non-coding RNAs are now attracting increased attention as robust regulators of 
various biological processes, including cancer progression. The micro-RNAs (miRs) are a 
class of conserved small non-coding RNA’s of 17-25 nucleotides in length that regulate gene 
expression by either repressing the translation or causing degradation of multiple target 
mRNAs. MiR genes represent about 1% of the genome in different species and it is 
estimated that about 30% of the protein-coding genes in the human genome are regulated by 
miRs (Wang & Sen, 2011). These miRs play a central role in the regulation of cellular 
functions, such as migration, invasion and stem cell functions (Vincent et al., 2011). 
Extensive mapping of the known miR genes revealed that these are often located in the 
genomic intervals rearranged in cancers including those displaying amplification, loss of 
heterozygosity, common breakpoints and fragile sites. Furthermore, functional analyses 
suggest that miRs play roles in cancer initiation, invasion and progression processes and, 
therefore, may prove to be informative biomarkers of detection, diagnosis and prognosis 
besides being potential targets of therapy (Wang & Sen, 2011).  
Over 300 miRs have been identified, and widespread alterations in these miRs have been 
recognized in various types of cancer, including pancreatic cancer, and seem to contribute to 
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their development and progression (see table 1, modified from (Wang & Sen, 2011)). MiR 
signatures specific for normal pancreas, chronic pancreatitis and cancer tissues have been 
identified and have been proposed to represent helpful markers for differential diagnosis of 
pancreatic cancer from chronic inflammatory disease of the pancreas and even other tumors 
(Hamada & Shimosegawa, 2011)(Vincent et al., 2011)(Wang & Sen, 2011). In addition, these 
differential-expressing miRs can also be profiled in blood as a minimally invasive biomarker 
assay for pancreatic cancer. This finding is extremely promising since there is no reliable 
biomarker assay, much less of minimally invasive nature, currently available for early 
detection, diagnosis and predicting prognosis of pancreatic cancer patients.  
microRNA  Expression profile  References 
Let-7f-1  Up  (Lee et al., 2007) 
Let-7d  Up  (Lee et al., 2007) 
miR-10  Up  (Bloomston et al., 2007)(Zhang et al., 2009b) 
miR-15b  Up  (Lee et al., 2007)(Zhang et al., 2009b) 
miR-16-1  Up  (Lee et al., 2007) 
miR-21  Up  
(Lee et al., 2007)(Bloomston et al., 
2007)(Zhang et al., 2009b)(Mees et al., 2010) 
miR-23  Up  (Bloomston et al., 2007) 
miR-24  Up  (Lee et al., 2007) 
miR-31  Up  
(Szafranska et al., 2007) 
(Szafranska et al., 2008)  
miR-92  Up  (Lee et al., 2007) 
miR-95  Up  (Zhang et al., 2009b) 
miR-96  Down  
(Szafranska et al., 2007) 
(Szafranska et al., 2008) 
miR-99  Up  (Bloomston et al., 2007) 
miR-100 Up  (Lee et al., 2007)(Bloomston et al., 2007) 
miR-103  Up  (Bloomston et al., 2007)(Zhang et al., 2009b) 
miR-107  Up  
(Lee et al., 2007)(Bloomston et al., 
2007)(Zhang et al., 2009b) 
miR-125  Up  (Lee et al., 2007)(Bloomston et al., 2007) 
miR-130b Down  
(Szafranska et al., 2007)(Bloomston et al., 
2007)(Szafranska et al., 2008) 
miR-139  Down  (Lee et al., 2007) 
miR-142-P Down (Lee et al., 2007) 
miR-143  Up  
(Szafranska et al., 2007)(Bloomston et al., 
2007)(Szafranska et al., 2008) 
(Zhang et al., 2009b) 
miR-145  Up  (Szafranska et al., 2008)(Zhang et al., 2009b) 
miR-146  Up  
(Szafranska et al., 2007) 
(Bloomston et al., 2007) 
miR-148a Down  
(Szafranska et al., 2007) 
(Bloomston et al., 2007) 
(Szafranska et al., 2008) 
miR-148b  Down  
(Szafranska et al., 2007) 
(Bloomston et al., 2007) 
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miR-155  Up  
 (Lee et al., 2007)(Szafranska et al., 
2007)(Szafranska et al., 2008) 
(Bloomston et al., 2007)(Zhang et al., 2009b) 
miR-181a  Up  (Lee et al., 2007)(Bloomston et al., 2007) 
miR-181b  Up  (Bloomston et al., 2007) 
miR-181c  Up  (Lee et al., 2007)(Bloomston et al., 2007) 
miR-181d  Up  (Bloomston et al., 2007) 
miR-186  Up  (Zhang et al., 2009b) 
miR-190  Up  (Zhang et al., 2009b) 
miR-194  Up  {Mees:2010fr} 
miR-196a  Up  
(Szafranska et al., 2007) 
(Szafranska et al., 2008)(Zhang et al., 2009b) 
miR-196b  Up  (Szafranska et al., 2007) 
miR-199a  Up  (Bloomston et al., 2007) 
miR-200b  Up (Zhang et al., 2009b){Mees:2010fr} 
miR-200c  Up  {Mees:2010fr} 
miR-203 Up (Ikenaga et al., 2010) 
miR-205  Up  
(Szafranska et al., 2007) 
(Bloomston et al., 2007) 
(Szafranska et al., 2008) 
miR-210  Up  
(Szafranska et al., 2007) 
(Bloomston et al., 2007)(Szafranska et al., 
2008)(Zhang et al., 2009b) 
miR-212  Up  (Lee et al., 2007) 
miR-213  Up  (Bloomston et al., 2007) 
miR-217  Down  
(Szafranska et al., 2007) 
(Szafranska et al., 2008) 
miR-220  Up  (Bloomston et al., 2007) 
miR-221  Up  
(Lee et al., 2007) 
(Szafranska et al., 2007)(Bloomston et al., 
2007)(Zhang et al., 2009b){Mees:2010fr} 
miR-222  Up  
(Szafranska et al., 2007) 
(Bloomston et al., 2007)(Zhang et al., 2009b) 
miR-223  Up  
(Szafranska et al., 2007)(Bloomston et al., 
2007)(Szafranska et al., 2008) 
(Zhang et al., 2009b) 
miR-301  Up  (Lee et al., 2007) 
miR-345  Down  (Lee et al., 2007) 
miR-375  Down  
(Szafranska et al., 2007) 
(Bloomston et al., 2007) 
(Szafranska et al., 2008) 
miR-376a Up  (Lee et al., 2007) 
miR-424  Up  (Lee et al., 2007) 
miR-429  Up  {Mees:2010fr} 
Table 1. Deregulated microRNAs in pancreatic ductal adenocarcinoma (modified from 
(Wang & Sen, 2011)). 
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In addition, successful therapeutic targeting of miRs (silencing, antisense blocking and miR 
modification of oncogenic miRs) also holds significant promise towards improved clinical 
management of patients with cancer, especially those with pancreatic carcinomas, since 
these patients have very limited treatment options available at this time (Wang & Sen, 
2011)(Rachagani et al., 2010).  
3.3 Glucose transporter isoforms (GLUT) 
Malignant cells have high constitutive glucose uptake and metabolism compared with 
normal cells (Pizzi et al., 2009). A family of glucose transporter isoforms (GLUT), which is 
currently composed of 13 members, facilitates the entry of glucose into cells. These are 
passive carriers and function as an energy-independent system that transports glucose 
down a concentration gradient. GLUT-1, a member of this family, is considered to be the 
predominantly upregulated glucose transporter in malignant epithelial tissue and 
mesothelium, and has been found to correlate with biological behavior in various 
malignancies (Basturk et al., 2011).  
Various studies have shown a close relationship between GLUT-1 expression and tumor 
aggressiveness and poor prognosis in squamous cell carcinoma of the head and neck and in 
carcinomas of the lung, stomach, gallbladder, colorectum, kidney, bladder, ovary and 
cervix. An increased GLUT-1 expression has also proved to be associated with pancreatic 
cancer invasiveness both in vitro and in vivo (Basturk et al., 2011). However, literature data 
regarding the prognostic significance of immunohistochemical GLUT-1 expression in 
pancreatic ductal adenocarcinoma are limited and non consistent, as a prognostic 
significance of GLUT-1 expression has been found by some research groups (Sun et al., 
2007)(Pizzi et al., 2009) and not by the other (Lyshchik et al., 2007). Differences can be 
ascribed to heterogeneity of histological types of pancreatic cancer and to the different 
scoring systems. Overall, GLUT-1 overexpression is regarded as a relative early event in 
pancreatic carcinogenesis and may be ascribed to local hypoxia. Furthermore, GLUT-1 
expression seems to correlate to a higher glucose uptake in undifferentiated and highly 
proliferative pancreatic cancer cells (Pizzi et al., 2009). Moreover, GLUT-1 promotes cellular 
invasiveness in pancreatic cancer, which is matrix metalloproteinase 2 (MMP2)-dependent, 
with MMP-2 being transcriptionally activated by increased GLUT-1 levels (Ito et al., 2004). 
In addition, an increased expression of GLUT-1 molecules in pancreatic tumors has been 
suggested to contribute to the higher rate of fluorine 18 fluorodeoxyglucose (18F-FDG) 
uptake into tumor cells compared with normal pancreatic tissue, as determined by 
standardized uptake value (SUV). Also, SUV has been found to be a predictor of survival in 
patients with ductal adenocarcinomas. Therefore, in addition to being of diagnostic value 
imaging-wise, GLUT-1 may also be a potential therapeutic target to limit glucose uptake 
and metabolism, thereby limiting the proliferative potential of malignant cells (Basturk et 
al., 2011). Apigenin, a flavonoid with significant anti-proliferative properties that inhibit 
pancreatic cancer cell proliferation, has been shown to inhibit glucose uptake as well as both 
GLUT-1 mRNA and protein expression in human pancreatic cancer cell lines. In addition, 
the PI3K/Akt pathway may be involved in mediating apigenin’s effects on downstream 
targets such as GLUT-1 (Melstrom et al., 2008). However, literature regarding the biological 
significance of GLUT-1 expression in pancreatic neoplasia has been limited and 
controversial (Basturk et al., 2011).  
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3.4 Human equilibrative nucleoside transporter 1 (hENT1) 
Gemcitabine, a pyrimidine nucleoside analogue, has clinically important activity in 
advanced and metastatic pancreatic adenocarcinoma and for which it is now the standard of 
care (Maréchal et al., 2009)(Ansari et al., 2011). Gemcitabine is a prodrug that is 
phosphorylated by deoxycitidine kinase to its mononucleotide in the rate-limiting step of its 
cellular anabolism. Subsequent nucleotide kinases convert gemcitabine monophosphate to 
its active metabolites, gemcitabine diphosphate and triphosphate. Permeation of 
gemcitabine through the plasma membrane requires specialized integral membrane 
nucleoside transporter proteins. Among these transporters, the major mediators of 
gemcitabine uptake into human cells appear to be the human equilibrative nucleoside 
transporter 1 (hENT1) and to a lesser extent the human conservative nucleoside transporter 
3 (hCNT3) (Maréchal et al., 2009). Recently, it was reported that tissue mRNA levels of the 
hENT1, which mediates the cellular entry of gemcitabine, correlated with survival (Ansari et 
al., 2011). Several subsequent immunohistochemically based studies demonstrated that 
hENT-1 holds promise as an independent predictive marker to identify those likely to 
benefit from gemcitabine based monotherapy (Morinaga et al., 2011)(Spratlin et al., 
2004)(Farrell et al., 2009) and gemcitabine based chemoradiotherapy (Maréchal et al., 
2009)(Murata et al., 2011). In addition, the expression of hENT1 provides independent 
prognostic information in untreated pancreatic carcinoma patients as well as those treated 
with adjuvant gemcitabine-based therapy (Kim et al., 2011b)(Maréchal et al., 2009). Whether 
these assays provide sufficient predictive information to guide treatment decision requires 
prospective evaluation in randomized clinical trials. However, the consistency and strength 
of the accumulating preclinical and translational data suggest that nucleoside transporters 
play an important role in clinical outcomes after gemcitabine adjuvant chemotherapy for 
pancreatic cancer (Maréchal et al., 2009).  
3.5 Conclusion 
Although the tumor node metastasis classification provides important prognostic 
information, it permits only crude stratification of clinical outcome for patients with 
pancreatic cancer. Although some potential markers were identified, a high degree of 
inconsistency still exists between reports. Validation through large multicenter prospective 
studies using standardized protocols is still needed. Considering the complexity of the 
disease, it seems reasonable to hypothesize that panels of markers, rather than single 
proteins, might become useful (Ansari et al., 2011).  
4. Gastric cancer 
4.1 Introduction  
Gastric cancer is one of the most common tumors and remains the second leading cause of 
cancer death worldwide (Gravalos & Jimeno, 2008)(Wagner & Moehler, 2009). Gastric cancer 
is a heterogeneous disease divided in at least two different tumor entities, the intestinal and 
the diffuse form, with difference in epidemiology, cause, pathogenesis and disorder. The 
development of the intestinal form, usually in older patients, is related to Helicobacter pylori 
and usually located in the corpus and the antrum and related to preexisting corpus 
predominant atrophic gastritis, followed by intestinal metaplasia. In contrast, the diffuse 
www.intechopen.com
 
Biomarkers in Gastrointestinal Cancer: Focus on Colon, Pancreatic and Gastric Cancer 63 
form is usually poorly differentiated, located most frequently in the proximal stomach and 
its incidence is rising at an alarming rate in overweight young men suffering from 
gastroesophageal reflux. Diffuse type cancers have usually a worse prognosis (Wagner & 
Moehler, 2009).  
Surgical resection remains the mainstay of treatment and cure in localized, non-metastatic 
gastric cancer while no globally accepted consensus exists on the best treatment regimen to 
be used in advanced gastric cancer (De Vita et al., 2010)(Lorenzen & Lordick, 2011). At 
present, the combination of a fluoropyrimidine and a platinum analogue either alone or in 
combination with a third drug such as an antracycline or taxanes are the most effective 
combinations resulting in a median survival of 8-10 months (Lorenzen & Lordick, 2011). 
These observations suggest the need for new therapeutic approaches, based on the 
implementation of predictive biomarkers, to further improve the outcome of patients with 
advanced gastric cancer (De Vita et al., 2010)(Wagner & Moehler, 2009)(Lorenzen & Lordick, 
2011). A better understanding of the molecular basis of cancer has contributed to the 
development of rationally designed molecular targeted therapies, which interfere with the 
signaling cascades involved in cell differentiation, proliferation and survival (Gravalos & 
Jimeno, 2008). Recently, the evidence that upregulation of signaling pathways of EGFR-
family plays a central role in cell differentiation, proliferation, and survival has supported 
the development of antitumor strategies against these targets (De Vita et al., 2010). One of 
the most considerable innovative targets in human cancer is the HER family.  
4.2 HER2 
The epidermal growth factor receptor (EGFR) family is composed of four members: HER1 
also known as EGFR1, HER2, HER3 and HER4, amongst which the EGFR1 and HER2 
represents targets for drugs currently under development for gastric cancer (Wagner & 
Moehler, 2009). The HER2 protein is a 185 kDa transmembrane tyrosine kinase (TK) receptor 
encoded by a gene located on chromosome 17q21, with an extracellular ligand-binding 
domain, a short transmembrane domain and an intracellular domain with TK activity. Up to 
now, no ligands have been identified for its extracellular domain, but it seems to be the 
preferred heterodimerization partner for other members of the HER family (De Vita et al., 
2010). HER2 functions as an oncogene and its amplification or overexpression plays a 
central role in the initiation, progression and metastasis of some common cancers. Aberrant 
HER2 expression or function has been implicated in about 10-34% of invasive breast cancers. 
In addition, HER 2 also appears to be overexpressed in colon, bladder, ovarian, 
endometrium, lung, uterine cervix, head and neck, and esophageal carcinomas. The first 
description of HER2 overexpression in gastric cancer, using IHC, was reported in 1986. 
Since then, a number of studies have confirmed these findings, reporting a HER2 positivity 
rate in a wide range (6-35%) of gastric carcinomas. Moreover, HER2 expression varies 
depending on histology and on primary tumor location (Lorenzen & Lordick, 2011)(De Vita 
et al., 2010). The randomized open-label, multinational phase III ToGA (Trastuzumb for 
Gastric Cancer) trial, in which by now the largest population of 3807 gastric cancers were 
centrally screened for HER2 gene amplification (Fluorescent in situ hybridization (FISH)) 
and HER2 protein overexpression (IHC 3+), reported a HER2 positivity of 22.1%, with a 
high degree of concordance between IHC and FISH (87,2%). Furthermore, HER2 positivity 
rates were found to be higher in esophagogastric junction cancer than in gastric cancer and 
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in intestinal cancer than diffuse or mixed type (Lorenzen & Lordick, 2011)(Croxtall & 
McKeage, 2010).  
Trastuzumab, a recombinant humanized IgG1 monoclonal antibody directed against the 
extracellular domain of HER2, in combination with chemotherapy agents, has recently 
received approval in the EU and USA for treatment of metastatic HER2-positive gastric 
cancer without prior anti-cancer treatment for metastatic disease (Croxtall & McKeage, 
2010).  
4.3 HER2 as prognostic factor in gastric cancer  
The TNM stage is the most important prognostic factor for gastric cancer. Prognosis, 
however, varies among patients in the same stage. Therefore, additional classification 
parameters, like HER2 need to be defined in addition to the TNM and the classical 
pathological characteristics of the tumor in order to better identify the biological subset of 
this disease (Gravalos & Jimeno, 2008). The role of HER2 as prognostic marker in gastric 
cancer has been controversial because some of the initial studies failed to find an association 
with outcome (Zhang et al., 2009a)(De Vita et al., 2010)(Gravalos & Jimeno, 2008)(Lorenzen 
& Lordick, 2011). Other authors, however, reported a direct correlation between HER2 
overexpression and poor outcome (Ananiev et al., 2011)(Kim et al., 2011a)(Im et al., 2005). 
However, the largest study to date investigating the prognostic significance of HER2 
expression in 924 gastric cancer patients showed that HER2 expression is not related to 
gastric cancer patients outcome (Grabsch et al., 2010). Chua et al. (Chua & Merrett, 2011) 
performed a systematic examination of the literature to identify translational studies that 
correlated HER2 with clinicopathologic markers and/or survival. This review included 49 
studies totaling 11,337 patients. IHC was most commonly used to assess HER2 expression, 
identifying a median rate of 18% of gastric cancer demonstrating HER2 overexpression. In 
patients with and without HER2 overexpression, the median 3-year disease-free survival 
rate was 58% and 86%, respectively. Of the 35 studies reporting the impact of HER2 
overexpression on survival, 20 studies (57%) reported no difference in overall survival, two 
studies (6%) reported significantly longer overall survival in patients with HER2 
overexpression and 13 studies (37%) reported significantly poorer overall survival in 
patients with HER2 overexpression. HER2 overexpression appears to be associated with 
poorer survival and with intestinal-type gastric cancer in this group of patients for whom 
majority undergone curative gastrectomy. Results of the ToGA trial, which are discussed 
below, seem to refute this suggestion as demonstrated by the longer than expected survival 
of patients in the control arm, who received chemotherapy alone. However possible 
confounding factors, such as the wide use of second line treatment and the better prognosis 
associated with the intestinal histology, should be kept in mind when interpreting these 
results (Fornaro et al., 2011). In addition, these conflicting results could be due to the lack of 
a standardized definition of HER2 positivity in gastric cancer (De Vita et al., 2010)(Lorenzen 
& Lordick, 2011).  
Hence, definitive answers about the prognostic role of HER2 in gastric cancer and gastric-
esophageal cancer cannot be derived from the available data, which thus emphasizes the 
need for further research in the field (Fornaro et al., 2011).  
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4.4 Trastuzumab and the predictive role of HER2 in gastric cancer 
Trastuzumab, a recombinant humanized IgG1 monoclonal antibody directed against the 
extracellular domain of HER2, induces antibody-dependent cellular cytotoxicity, inhibits 
HER2-mediated signaling and prevents cleavage of the extracellular domain of HER2. In 
HER2 positive breast cancer, trastuzumab has demonstrated survival benefits for patients 
with early and metastatic disease and is now the standard of care (Bang et al., 2010)(Croxtall 
& McKeage, 2010). Several studies indicate antitumor activity of trastuzumab in 
overexpressing HER2 human gastric cancer cell lines or xenograft models (Matsui et al., 
2005)(Tanner et al., 2005)(Fujimoto-Ouchi et al., 2007). Most of these studies used the NCI-
N87 and or 4-1ST gastric cell lines, which show HER2 expression in IHC and gene 
amplification on FISH. These studies showed that trastuzumab suppressed the growth of 
human gastric cancer with HER2 overexpression in vitro and in vivo and improved the 
survival of mice with peritoneal dissemination and ascites of gastric cancer. In addition, 
trastuzumab administered in combination with chemotherapy agents for gastric cancer 
showed potent antitumor activity, which was significantly greater than did trastuzumab or 
the chemotherapy agents as single treatments. A three-drug combination of capacetabine, 
cisplatin, and trastuzumab achieved remarkable tumor growth inhibition in the N87 model 
(Fujimoto-Ouchi et al., 2007)(Kim et al., 2008)(Gravalos & Jimeno, 2008). In addition, there 
are currently no data regarding resistance to trastuzumab in gastric cancer cells and there 
are no in vitro tests available to enable the prediction of resistance (Croxtall & McKeage, 
2010).  
Based on these results there was a strong rationale to investigate the clinical potential of 
trastuzumab in gastric cancer patients. Several preliminary single-arm phase II trials paved 
the way for the registration of the large, randomized controlled, open label, multicenter, 
international phase III trial which was undertaken in 24 centers in Aisa, Central and South 
America and Europe. The objective of this “Trastuzumab for Gastric Cancer” (ToGA) study 
was to assess the clinical efficacy and safety of trastuzumab added to chemotherapy for first-
line treatment of advanced gastric or gastro-esophageal junction cancer with overexpression 
of HER2. Tumors were centrally tested for HER2 status with IHC (Hercep test) and FISH. 
Because of the inherent difference between breast and gastric tumors, notably tumor 
heterogeneity and the occurrence of baso(lateral) membrane staining, a new set of IHC 
scoring criteria were developed that are specific for gastric cancer. Patients were eligible if 
their tumor samples were scored as 3+ on IHC or if they were FISH positive (Bang et al., 
2010) (Bang et al., 2010). As mentioned above, 22,1% of all gastric cancer screened in the 
ToGA trial were HER2-positive, which is broadly comparable with the incidence in breast 
cancer. Moreover, there was a high degree of concordance between IHC and FISH. 
Therefore, IHC is suitable for primary testing of HER2 positivity in gastric cancer with a 
score of IHC3+ indicating eligibility for treatment with trastuzumab, IHC2+ should be 
retested by FISH to confirm HER2 positivity and a score of IHC0 or 1+ should be considered 
as HER2-negative. The incidence of HER2 positivity differed according to tumor location 
and histological subtype. There was a significantly greater incidence of HER2-positive 
cancers of the oesophagogastric junction than the stomach and in intestinal than diffuse or 
mixed cancers. In addition, the incidence of HER2 positive gastric cancers was similar 
between Europe and Asia, but varied between countries (Croxtall & McKeage, 2010). 
Patients who satisfied all eligibility criteria (594 patients) were randomized in a 1:1 ratio and 
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584 patients received treatment with trastuzumab plus chemotherapy (5FU or capecitabine 
and cisplatin) for six cycles or chemotherapy alone (Lorenzen & Lordick, 2011). The primary 
objective was to compare overall survival in both treatment arms, and the secondary 
objectives were to compare progression-free survival, time to progression, overall response 
rate, control disease, duration of response, and quality of life (Gravalos & Jimeno, 2008). The 
primary endpoint of the study was met: trastuzumab significantly improved overall 
survival by nearly 3 months (median 11.1 vs 13.8 months) (Lorenzen & Lordick, 2011). In 
addition, an exploratory post-hoc analysis showed that trastuzumab plus chemotherapy 
substantially improved overall survival in patients with high expression of HER2 protein 
(IHC2+/FISH+ or IHC3+, 16 months) compared with patients with low expression of HER2 
protein (IHC0 or 1+ and FISH+) (Bang et al., 2010). The secondary endpoints also showed 
significant improvements when trastuzumab was added to chemotherapy. The addition of 
trastuzumab to chemotherapy did not increase toxic effects associated with standard 
fluoropyrimidine-based and platinum-based chemotherapy and therefore trastuzumab can 
be combined with standard chemotherapy without affecting the overall safety profile. On 
the basis of these findings, trastuzumab can be considered as a new standard option for 
patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer when 
combined with a chemotherapy regimen consisting of capecitabine plus cisplatin or 
fluorouracil plus cisplatin (Bang et al., 2010).  
On the basis of this evidence, in January 2010 the EMEA and on 20 October 2010, the US 
FDA granted approval for trastuzumab in combination with cisplatin and fluoropyrimidine 
(either capecitabine or 5FU), for the treatment of metastatic HER-2 positive gastric or gastro-
oesophageal junction adenocarcinoma who have not received prior treatment for metastatic 
disease (Lorenzen & Lordick, 2011).  
Further studies are necessary to investigate the role of trastuzumab in curative gastric cancer 
treatment, as well its role as monotherapy, maintenance therapy and second line treatment 
in the palliative setting. Furthermore, additional predictive markers are needed besides a 
HER2-positive status. In addition, there is an urgent need to improve the knowledge of the 
mechanisms involved in anti-HER2 sensitivity or resistance, in order to develop other 
rationally targeted agents in the near future (Fornaro et al., 2011).  
4.5 Conclusion 
Since there is no internationally accepted standard of care for gastric or gastro-esophageal 
cancer patients and survival remains poor, new therapeutic strategies are needed. There is 
mounting evidence of the role of HER2 overexpression in patients with gastric cancer. HER2 
overexpression has been correlated to poor outcome and more aggressive disease. 
Furthermore, the positive results of the randomized phase III ToGA trial have opened up 
new frontiers. Trastuzumab not only represents a new and effective therapeutic option, but 
has also stimulated the search for predictive marker in order to refine patient selection 
(Fornaro et al., 2011). Trastuzumab represents a new reference treatment for patients with 
HER2-positive metastatic gastric or gastro-esophageal cancer. Routine HER2 testing is 
suggested for all patients with advanced disease. Other agents directed against members of 
the HER family (like lapatinib) are currently under investigation (Lorenzen & Lordick, 
2011).  
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5. General conclusion 
Ample data shows that only a limited portion of patients may benefit from anti-cancer 
treatments currently used in the clinic. Personalized cancer medicine, based on genetic 
profiling of individual tumors and biomarkers, is regarded as the treatment strategy of the 
future. In this review the most promising biomarkers in colorectal, pancreatic and gastric 
cancer were discussed (table 2). Currently, the only biomarker that has made it into clinical 
practice for colorectal cancer is KRAS mutation for the selection of patients eligible for 
cetuximab therapy. Furthermore, evidence shows that other molecular alterations, such as 
BRAF, PIK3CA (exon-20) mutations or loss of PTEN expression, could preclude response to 
EGFR moAb. 
Location Predictive Prognostic Stage 
Colorectal cancer KRAS 
 
PIK3CA exon 20 mut.
 
 
 
BRAF 
Clinical stage  
(since 2008) 
Preclinical stage 
Preclinical stage 
Pancreatic cancer CA19-9 
hENT1 
miRs 
 
 
hENT1 
miRs 
GLUT 
Clinical stage 
Preclinical stage 
Preclinical stage 
Preclinical stage 
Gastric cancer HER2  
 
HER2 
Clinical stage  
(since 2010) 
Preclinical stage 
Table 2. The most promising biomarkers in colorectal, pancreatic and gastric cancer 
summarized. 
Improved screening for early diagnosis is essential in order to increase the rate of curatively 
resectable pancreatic carcinomas, thereby ameliorating patient’s prognosis. A relatively non-
invasive, cost efficient possibility could be provided by the measurement of disease-specific 
markers in peripheral blood. However, only a few markers have shown promising results in 
recent studies with CA19-9 being the most widely investigated and evaluated single marker 
(Bünger et al., 2011).  
In patients with gastric cancer there is mounting evidence of the role of HER2 
overexpression since it has been correlated to poor outcome and more aggressive disease. 
Furthermore, HER 2 overexpression was found to be predictive for treatment of gastric 
cancer patients with trastuzumab. Routine HER2 testing is now suggested for all patients 
with advanced disease.  
Given the importance of biomarkers in this era of targeted therapies more and especially 
prospective randomized trials are necessary. 
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